181 related articles for article (PubMed ID: 10985897)
1. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
2. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a non-invasive mouse reporter model for monitoring in vivo pdx-1 promoter activity.
Shiraiwa T; Kaneto H; Miyatsuka T; Kato K; Yamamoto K; Kawashima A; Kajimoto Y; Matsuoka TA; Matsuhisa M; Yamasaki Y; Fujitani Y
Biochem Biophys Res Commun; 2007 Sep; 361(3):739-44. PubMed ID: 17678877
[TBL] [Abstract][Full Text] [Related]
4. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
5. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
6. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
7. Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts.
Chaudhuri TR; Cao Z; Krasnykh VN; Stargel AV; Belousova N; Partridge EE; Zinn KR
Technol Cancer Res Treat; 2003 Apr; 2(2):171-80. PubMed ID: 12680799
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
9. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2002 Feb; 84(2):228-34. PubMed ID: 11812079
[TBL] [Abstract][Full Text] [Related]
10. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
11. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
12. Activation of cancer-specific gene expression by the survivin promoter.
Bao R; Connolly DC; Murphy M; Green J; Weinstein JK; Pisarcik DA; Hamilton TC
J Natl Cancer Inst; 2002 Apr; 94(7):522-8. PubMed ID: 11929953
[TBL] [Abstract][Full Text] [Related]
13. Optimization of in vitro vascular cell transfection with non-viral vectors for in vivo applications.
Elmadbouh I; Rossignol P; Meilhac O; Vranckx R; Pichon C; Pouzet B; Midoux P; Michel JB
J Gene Med; 2004 Oct; 6(10):1112-24. PubMed ID: 15386736
[TBL] [Abstract][Full Text] [Related]
14. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
16. The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line.
Shoukrun R; Veenman L; Shandalov Y; Leschiner S; Spanier I; Karry R; Katz Y; Weisinger G; Weizman A; Gavish M
Pharmacogenet Genomics; 2008 Nov; 18(11):977-88. PubMed ID: 18806692
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring early toxicity of heavy metals including Hg using a HSE-SEAP reporter gene].
Yu ZJ; Yang Q; Yang XD; Wang K
Zhongguo Zhong Yao Za Zhi; 2006 Aug; 31(16):1346-9. PubMed ID: 17061558
[TBL] [Abstract][Full Text] [Related]
18. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
20. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity.
Banzato A; Bobisse S; Rondina M; Renier D; Bettella F; Esposito G; Quintieri L; Meléndez-Alafort L; Mazzi U; Zanovello P; Rosato A
Clin Cancer Res; 2008 Jun; 14(11):3598-606. PubMed ID: 18519794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
